Updates

** Shares of Australia's Telix Pharmaceuticals TLX.AX gain 9.2% so far this week, set for their best week since week-ended April 10

** Stock, however, down 4% at A$18.58 on Friday

** Jefferies says Telix’s ProstACT trial to treat prostate cancer is progressing as scheduled for U.S. entry, with interim radiographic progression-free survival analysis data anticipated in 2027

** Medtech firm said on Thursday the U.S. drug regulator has cleared Part 2 of its global ProstACT trial for U.S. expansion, deeming Part 1 safety data adequate

** Brokerage expects the Investigational New Drug amendment to be approved, clearing U.S. recruitment for the randomised portion of the Phase 3 study

** ProstACT trial is being done to investigate TLX591 as a targeted therapy for metastatic castration‑resistant prostate cancer

** Stock up 49% YTD